FDA Clears Elecsys Phospho-Tau Blood Test for Alzheimer Disease

The FDA cleared the first and only single-biomarker blood test that can both rule in and rule out amyloid pathology associated with Alzheimer disease using one set of validated cutoffs across primary and specialty care, according to a news release from Roche. The development stands to move amyloid assessment out of specialty memory centers and into the settings where most patients with cognitive complaints are first seen.¹

For pharmacists, the clearance signals a near-term shift in how early Alzheimer disease evaluation is triggered, referred, and followed and a growing need to counsel patients and caregivers on what a blood-based result does and does not mean.

What the FDA Cleared

The FDA cleared the Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test (Roche, Eli Lilly and Company) to aid in identifying amyloid pathology associated with Alzheimer disease in individuals 55 years and older with signs, symptoms, or complaints of cognitive decline. The assay returns positive, intermediate, or negative result categories to support assessment of the likelihood of amyloid pathology, using the same validated clinical cutoffs in both primary and specialty care. Roche describes the approach as one assay, one biomarker, and one set of cutoffs.¹

Importantly, the assay is not intended as a stand-alone test. Results should be interpreted alongside other diagnostic tools and clinical information, and Roche notes the test's safety and effectiveness have not been established for predicting the development of dementia or other neurologic conditions or for monitoring the effect of therapeutic products.¹

Why It Matters for Earlier Diagnosis

The clearance targets a long-standing diagnostic gap. An estimated 75% of people living with dementia remain undiagnosed, and those who are diagnosed often wait years after symptoms first appear. Traditional methods for assessing amyloid pathology—positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing—can be costly, invasive, and difficult to access outside specialty centers.

Revised criteria from an Alzheimer's Association workgroup have formalized the role of biomarkers in diagnosis and staging, and consensus recommendations have laid out acceptable performance standards for blood-based amyloid tests, setting the stage for tools like this one to enter routine evaluation.^2-6

A minimally invasive blood draw that integrates into existing clinical and laboratory workflows may help clinicians assess amyloid likelihood earlier and identify which patients warrant further evaluation or specialist referral.¹

The Pharmacist's Role

Pharmacists are often the health care professional a patient with early cognitive changes encounters most frequently, whether through medication refills, adherence check-ins, or routine counseling—positioning them to notice missed fills or functional decline that may warrant follow-up. As amyloid-targeting disease-modifying therapies now require confirmation of amyloid pathology before initiation, an accessible blood-based option upstream of PET or CSF testing could streamline the path from symptom recognition to appropriate treatment candidacy.

Roche notes the test is designed to run on its installed base of more than 4500 cobas laboratory instruments in the US, which the company says supports broad access without additional instrumentation. Pharmacists counseling patients and caregivers should be prepared to explain that a positive result is not a diagnosis on its own, that an intermediate result may prompt additional testing, and that the assay does not predict whether or when dementia will develop.¹

REFERENCES

1. Roche receives FDA clearance for Elecsys pTau217, advancing Alzheimer's disease assessment across primary and specialty care. News release. Roche. Released August 24, 2026. Accessed August 25, 2026. https://diagnostics.roche.com/us/en/news-listing/2026/fda-elecsys-ptau217-alzheimers-blood-test.html

2. World Alzheimer Report 2021: Journey through the diagnosis of dementia. Alzheimer's Disease International; McGill University. Released September 21, 2021. Accessed August 25, 2026. https://www.alzint.org/resource/world-alzheimer-report-2021/

3. Kusoro O, Roche M, Del-Pino-Casado R, et al. Time to diagnosis in dementia: A systematic review with meta-analysis. Int J Ger Psych. 2025;40(7):e70129. doi:10.1002/gps.70129

4. Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. et al. The role of amyloid PET in imaging neurodegenerative disorders. J Nucl Med. 2022;63(Suppl 1):13S-19S. doi:10.2967/jnumed.121.263195

5. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20(8):5143–5169. doi:10.1002/alz.13859

6. Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer's Disease. Nat Rev Neurol. 2024;20(7):426–439. doi:10.1038/s41582-024-00977-5